Winslow Capital Management LLC Increases Stock Holdings in Eli Lilly and Company $LLY

Winslow Capital Management LLC grew its stake in Eli Lilly and Company (NYSE:LLY) by 4.8% during the second quarter, HoldingsChannel reports. The fund owned 1,194,806 shares of the company’s stock after acquiring an additional 54,522 shares during the quarter. Eli Lilly and Company comprises about 3.1% of Winslow Capital Management LLC’s holdings, making the stock its 7th largest position. Winslow Capital Management LLC’s holdings in Eli Lilly and Company were worth $931,387,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in LLY. Wealth Preservation Advisors LLC bought a new position in Eli Lilly and Company in the first quarter worth about $27,000. Sumitomo Mitsui Financial Group Inc. purchased a new position in shares of Eli Lilly and Company in the 2nd quarter worth approximately $27,000. Financial Gravity Companies Inc. purchased a new position in shares of Eli Lilly and Company in the 2nd quarter worth approximately $31,000. Bare Financial Services Inc raised its stake in shares of Eli Lilly and Company by 263.6% during the 2nd quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock worth $31,000 after acquiring an additional 29 shares in the last quarter. Finally, Blume Capital Management Inc. lifted its position in Eli Lilly and Company by 46.7% during the second quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock valued at $34,000 after acquiring an additional 14 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

LLY has been the topic of a number of recent analyst reports. Weiss Ratings raised Eli Lilly and Company from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday. Daiwa America downgraded Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Sunday, August 17th. JPMorgan Chase & Co. upped their target price on Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the company an “overweight” rating in a research report on Tuesday, November 18th. CICC Research raised their price target on Eli Lilly and Company from $801.00 to $1,060.00 and gave the stock a “neutral” rating in a report on Thursday, November 13th. Finally, Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Three analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,087.32.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $1,009.26 on Monday. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,111.99. The business’s 50 day moving average price is $918.84 and its 200 day moving average price is $810.35. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. The firm has a market cap of $954.13 billion, a P/E ratio of 49.38, a P/E/G ratio of 1.12 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating the consensus estimate of $6.42 by $0.60. The business had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The business’s quarterly revenue was up 53.9% compared to the same quarter last year. During the same period in the previous year, the business posted $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, sell-side analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be given a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 29.35%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.